Conferences - Results from #140

ASCO 2023: ARASEC: Open-Label Study of Darolutamide Plus ADT vs ADT in mHSPC Using an External Control Arm June 3, 2023

ASCO 2023: Phase 2 Study of Batiraxcept as Monotherapy, in Combination with Cabozantinib, and in Combination with Cabozantinib and Nivolumab in Patients with Advanced Clear Cell Renal Cell Carcinoma June 3, 2023

ASCO 2023: Assessing PSA Levels as Prognostic of Overall Survival in Men with mHSPC June 3, 2023

ASCO 2023: Head-to-Head Effectiveness and Safety of Pembrolizumab plus Axitinib vs. Nivolumab plus Ipilimumab in Metastatic Renal Cell Carcinoma in the United States June 3, 2023

ASCO 2023: CASSIOPE: A Prospective Noninterventional Study of Cabozantinib Treatment Following Prior Vascular Endothelial Growth Factor - Targeted Therapy in Patients with Advanced Renal Cell Carcinoma June 3, 2023

ASCO 2023: Health-Related Quality of Life (HRQoL) of Risk-Based Patient Subgroups with Advanced Renal Cell Cancer (aRCC) Treated with Nivolumab plus Cabozantinib vs Sunitinib in the CheckMate 9ER Trial June 3, 2023

ASCO 2023: DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States June 3, 2023

ASCO 2023: A Phase I/II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Atezolizumab and Bevacizumab in Patients with Renal Cell Carcinoma June 3, 2023

ASCO 2023: Biomarker-Driven Prospective Clinical Trial in Renal Cell Carcinoma: Developing Machine Learning Models to Allocate Patients to Treatment Arms Using RNA Sequencing June 3, 2023

ASCO 2023: Determinants of Resistance to Nivolumab Monotherapy Investigated Through Genomic and Transcriptomic Analysis of Renal Cell Carcinoma Tumors from the HCRN GU16-260 Study June 3, 2023

ASCO 2023: Darolutamide and Time to Pain Progression by Disease Volume In ARASENS June 3, 2023

Temple Health and Fox Chase Cancer Center Researchers Reveal the Importance of Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer May 31, 2023

Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting May 30, 2023

AUA 2023: Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer: EMBARK May 3, 2023

AUA 2023: Role and Extent of Pelvic Lymph Node Dissection in PSMA Era May 3, 2023

AUA 2023: An Interim Analysis of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients With BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) Carcinoma in-situ (CIS) May 3, 2023

AUA 2023: Single Port Robotic Assisted Radical Prostatectomy, Technical Point of View May 3, 2023

AUA 2023: Infectious and Non-Infectious Complications Following Prostate Biopsy: A Randomized Clinical Trial May 3, 2023

Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting May 3, 2023

AUA 2023: Oligometastatic Disease—Who/Why for Directed Therapy May 2, 2023

Page 8 of 522